No Data
No Data
We Ran A Stock Scan For Earnings Growth And Giant Biogene Holding (HKG:2367) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can
Tracking Hong Kong stocks | Rise of domestic cosmetics in the market, institutions are bullish on top companies' penetration rate improvement (attached concept stocks).
Cosmetics lead the domestic industry growth, with market share continuing to rise.
HK Stocks Market | Juzi Bio (02367) rose over 3%, domestic products with improved quality-price ratio, company is expected to achieve a double play in the beauty and medical aesthetics business.
Zhītōng Finance APP learned that Juzi Biotech (02367) rose more than 3%, and as of press time, it has risen by 3.12% to HKD 41.90, with a turnover of HKD 60.6538 million. Swhy released research reports stating that as the domestic product's "quality-price ratio" increases, affordable consumption rises, and the penetration rate of mass markets increases, the bullish large single-product viscosity is strong, and the channel layout is diversified. The medical and aesthetic industry will continue to benefit from the rich supply of products on the supply side, and the industry will maintain healthy and standardized development. The bank pointed out that the restructuring collagen protein track is hot, which has helped the company's brand and category develop rapidly. It is expected that Juzi biotech's 24 H1 revenue growth rate will be about 43%.
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
Minsheng Securities: New round of consumer tax reform may bring new opportunities to the retail industry.
The first expansion of the collection scope mainly targets some high-end consumer goods. Experts from China University of Political Science and Law said that high-end watches, expensive jewelry, and precious stones and jade with mature regulatory conditions may be the first pilot projects.
[Brokerage Focus] Caitong Securities maintains its 'shareholding' rating for Juzi Biotechnology (02367), expecting the company's net profit to steadily increase.
Caitong Securities released a research report stating that Juzi Biology (02367) released its 618 sales report, showing high growth potential of its two famous beauty brands. 1. Kafu Mei's total GMV increased by more than 60% year-on-year in all channels and all cycles, among which Tmall/Douyin/JD.com/vipshop's YoY growth exceeded 50%/65%/100%/200%, respectively; 2. Kailijin's total GMV increased by more than 100% year-on-year in all channels and all cycles, among which Tmall/Douyin/JD.com/vipshop's YoY growth exceeded 70%/300%/200%/170%, respectively. The bank believes that under the background of continuous improvement of the beauty business and the expected approval of the three medical and beauty products,
No Data